Protalix BioTherapeutics (PLX) Revenue (2010 - 2026)
Protalix BioTherapeutics' quarterly Revenue came in at $33.8 million in Q1 2026, up 233.73% year-on-year from $10.1 million in Q1 2025, and up 269.98% quarter-over-quarter from $9.1 million in Q4 2025.
Protalix BioTherapeutics has reported Revenue for 17 years, with the latest figure at $33.8 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 233.73% year-over-year to $33.8 million; the trailing twelve-month figure through Mar 2026 stood at $76.4 million (up 27.8% YoY), and the FY2025 full-year result was $52.7 million, down 1.23% from the prior year.
- Revenue for Q1 2026 stood at $33.8 million, up from $9.1 million in the prior quarter.
- The five-year high for Revenue was $35.1 million in Q2 2023, with the low at $3.7 million in Q1 2024.
- Average Revenue over 5 years is $14.9 million, with a median of $13.5 million recorded in 2024.
- Year-over-year, Revenue jumped 300.72% in 2023 and plunged 61.59% in 2024.
- Tracing PLX's Revenue over 5 years: stood at $8.6 million in 2022, then advanced by 21.69% to $10.5 million in 2023, then surged by 73.74% to $18.2 million in 2024, then plunged by 49.93% to $9.1 million in 2025, then jumped by 269.98% to $33.8 million in 2026.
- The last three Revenue figures came in at $33.8 million (Q1 2026), $9.1 million (Q4 2025), and $17.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 33.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.75 Mn |
| Dec 31, 2025 | 9.12 Mn |
| Sep 30, 2025 | 17.85 Mn |
| Jun 30, 2025 | 15.66 Mn |
| Mar 31, 2025 | 10.11 Mn |
| Dec 31, 2024 | 18.22 Mn |
| Sep 30, 2024 | 17.96 Mn |
| Jun 30, 2024 | 13.47 Mn |
| Mar 31, 2024 | 3.75 Mn |
| Dec 31, 2023 | 10.49 Mn |
| Sep 30, 2023 | 10.35 Mn |
| Jun 30, 2023 | 35.08 Mn |
| Mar 31, 2023 | 9.59 Mn |
| Dec 31, 2022 | 8.62 Mn |
| Sep 30, 2022 | 14.18 Mn |
| Jun 30, 2022 | 8.75 Mn |
| Mar 31, 2022 | 16.09 Mn |
| Dec 31, 2021 | 8.55 Mn |
| Sep 30, 2021 | 12.05 Mn |
| Jun 30, 2021 | 6.43 Mn |
| Mar 31, 2021 | 11.32 Mn |
| Dec 31, 2020 | 19.50 Mn |
| Sep 30, 2020 | 10.79 Mn |
| Jun 30, 2020 | 10.97 Mn |
| Mar 31, 2020 | 21.65 Mn |
| Dec 31, 2019 | 13.98 Mn |
| Sep 30, 2019 | 14.25 Mn |
| Jun 30, 2019 | 12.25 Mn |
| Mar 31, 2019 | 10.44 Mn |
| Dec 31, 2018 | 1.76 Mn |
| Sep 30, 2018 | 663,000.00 |
| Jun 30, 2018 | 2.01 Mn |
| Mar 31, 2018 | 4.55 Mn |
| Dec 31, 2017 | 1.80 Mn |
| Sep 30, 2017 | 7.53 Mn |
| Jun 30, 2017 | 6.36 Mn |
| Mar 31, 2017 | 1.65 Mn |
| Dec 31, 2016 | 2.08 Mn |
| Sep 30, 2016 | 4.67 Mn |
| Jun 30, 2016 | 1.77 Mn |
| Mar 31, 2016 | 679,000.00 |
| Sep 30, 2015 | 1.34 Mn |
| Jun 30, 2015 | 1.34 Mn |
| Mar 31, 2015 | 1.69 Mn |
| Mar 31, 2014 | 6.70 Mn |
| Dec 31, 2013 | -8.12 Mn |
| Sep 30, 2013 | 2.28 Mn |
| Jun 30, 2013 | 2.26 Mn |
| Mar 31, 2013 | 3.57 Mn |
| Dec 31, 2012 | 1.17 Mn |
| Sep 30, 2012 | 3.72 Mn |
| Jun 30, 2012 | 26.11 Mn |
| Mar 31, 2012 | 3.86 Mn |
| Dec 31, 2011 | 2.36 Mn |
| Sep 30, 2011 | 1.13 Mn |
| Jun 30, 2011 | 764,000.00 |
| Mar 31, 2011 | 4.13 Mn |
| Dec 31, 2010 | 1.18 Mn |
| Sep 30, 2010 | 3.18 Mn |
| Jun 30, 2010 | 1.14 Mn |